MEDICAL AND SOCIAL ASPECTS OF BENIGN PROSTATIC HYPERPLASIA. LITERATURE REVIEW
Introduction.More than 40.0% of all diseases in men over 50 years fall at the share of the benign prostatic hyperplasia (BPH) that brings this disease into line of primary medical and social problems. Moreover, according toWHO’s demographic researches the population of the planet grows old, thus rate of incidence of this pathology is predicted. BPH significantly reduces quality of men’s life which is connected with various inappropriate urination, general asthenization of organism, change of psychoemotional state and erectile dysfunctions [4,17,21,68].
Despite some differences in statistic data, we see what high incidence and what impact on quality of life this disease has, howlower urinary tract symptoms and sexual disordersdue to BPH influence psychoemotional state of the patient. Methods of improvement in quality of life are offered, extensive information on modern achievements in this area is given. It is obvious that for timely diagnostics and development of effective measures of BPH prevention and rehabilitation it is necessary to study intensively risk factors of development of this disease, their interrelation.
Purpose: To carry out systematic search of scientific literature concerning medical and social aspects of development of benign prostatic hyperplasia and their influence on quality of life of patients.
Search strategy: Search of scientific publications was carried out in the databases of evidential medicine ((Elsevier, Web of Science, PubMed, CochraneLibrary), in the electronic scientific libraries (CyberLeninka, websites of periodic medical publications of the CIS countries) and the electronic libraries of dissertations (dissercat.com, medical-diss.com, etc.). In total, it was found 13530 sources of literature. After automatic search and exception of the duplicated publications, we executed search of publications “manually” which allowed to reveal 70 sources of literature included in this review.
Results: At the present time increasing attention in literature, especially in foreign one, is paid to BPHproblems, risk factors of its development, influence of these factors on quality of men’s life. And this is not surprising because according to numerous epidemiological researches BPHis one of the most frequent diseases of men and averages 29 - 30% of the totalappealability of men according to different authors. But it is necessary to tell that these figures are relative. Many researchers,including foreign ones, underline thatthere is no timely diagnosis of this disease because of low appealability of men in view of different reasons, and there is no sufficient detectability at the primary medical level as the main patient stream goes through general practitioners. Other moment of incidence rateof BPHis inefficient measures of prevention, insufficient assessment of risk factors of this pathology as well as their influence not only on development of disease, but also on the prediction in general. Therefore development of effective measures of prevention and rehabilitation of patients withprostatic hyperplasia is necessary.
Conclusions: Thus, by the worked out sources of literature it can be seen how many publications are devoted to BPHproblems, how relevant it is in connection with progressive rate of incidence. Manifestations of BPHin the form of lower urinary tract symptoms and erectile dysfunction significantly reduce quality of life, lead to various neurotic disordersof men. Data of foreign authors on interrelation of lower urinary tract symptoms and erectile dysfunction and their influence on cardiovascular system, especially on their early diagnostics, are very interesting and evidential. It gives the chance to apply these recommendations for timely preliminary diagnostics of both states already at primary medical level. It is necessary, considering the most valuable evidential data of sources of literature, to develop measures of timely diagnostics, prevention and complex rehabilitation of patients with BPH
Asset M. Kussainov 1, Tolkyn A. Bulegenov 1
1 NJSC “Medical University of Semey”, Semey, Republic of Kazakhstan
1. Абдурахманов А.К. Медико-социальные факторы и первичная профилактика доброкачественной гиперплазии предстательной железы. Дис…канд.мед.наук. 2009г. 260с.
2. Аляева Ю.Г. Болезни предстательной железы // ГЭОТАР‑Медиа.2009. 240 с.
3. Гигиадзе О.В. Реабилитация больных доброкачественной гиперплазией после хирургического лечения. дисс. …д-ра мед. наук. 2006. 136с.
4. Досхожаев Б.К. Эпидемиология доброкачествен-ной гиперплазии предстательной железы в популяции мужчин старше 40 лет в Республике Казахстан // Вестник АГИУВ. 2012. №2. С. 676-70.
5. Елина Ю.А. Медико-социальная характеристика больных с заболеваниями предстательной железы и организационные основы профилактики. Дисс… канд.мед.наук. 2012г. 152с.
6. Измайлов Р.И. Оптимизация лечения больных доброкачественной гиперплазией предстательной железы больших размеров: дисс… канд.мед. наук . 2010. 139 с.
7. Калинина С.Н., Бурлака О.О., Александров М.С. Диагностика и лечение симптомов нижних мочевых путей и эректильной дисфункции у больных доброкачественной гиперплазией предстательной железы // Урологические ведомости. 2018. Т 8.№1.С.26-33.
8. Калинченко С.Ю., Тюзиков И.А. Заболевания предстатель ной железы и метаболический синдром: новая патогенетическая концепция (литературный обзор) // Медицинский алфавит. Больница. 2011. № 4. С. 38–43.
9. Камаев И.А. Актуальные проблемы медико-социальной помощи населению старших возрастных групп // Общественное здоровье и здравоохранение. Избранные лекции / Нижний Новгород. 2010. 165с.
10. Кирпатовский В.И., Фролова Е.В., Надточий О.Н. и др. Андрогенный дефицит и прогрессирование доброкачественной гиперплазии предстательной железы у больных с метаболическим синдромом: нет ли противоречия? // Андрология и генитальная хирургия.2017.№3. том18. С.10-18.
11. Корнев И.А. Алексеева Т.А., Аль-Шукри С.Х. Симптомы нижних мочевых путей у мужчин Северо-Западного региона Российской Федерации: анализ результатов популяционного исследования // Урологические ведомости .2016. Т.6. №1. С.5-9.
12. Кызласов П.С., Мартов А.Г., Попов С.В. Эректильная дисфункция после трансуретральной хирургии при доброкачественной гиперплазии предстательной железы // Вестник ВолгГМУ. 2017г. Выпуск 3(63). С.10-15.
13. Латышева В.Я., Аничкин В.В, Карпович Е.В. Оценка качества жизни больных с доброкачественной гиперплазией предстательной железы // Проблемы здоровья и экологии. Беларусь. 2006. №1(7). С.142-148.
14. Лопаткина Н.А.. Урология. Национальное руководство // ГЭОТАР‑Медиа. 2009. 1024 с.
15. Панович А.А. Организационные аспекты восстановительного лечения мужчин с доброкачественной гиперплазией предстательной железы. дис...канд. мед. наук. 2014г. 152с.
16. Пушкарь Д.Ю., Раснер И.П. Нарушение мочеиспускания и сексуальной функции у больных доброкачественной гиперплазией предстательной железы // Врач. 2008. №6. С.34-38.
17. Севрюков Ф.А. Комплексные медико-социальные и клинико-экономические аспекты профилактики и лечения доброкачественной гиперплазии предстательной железы: дисс. …д-ра мед.наук. 2012. 352с.
18. Севрюков Ф.А., Камаев И.А., Гриб М.Н. Факторы риска и качество жизни больных с доброкачественной гиперплазией предстательной железы // Российский медико-биологический вестник имени академика И.П. Павлова. №3. 2011 г. C. 48-51.
19. Тюзиков И.А., Братчиков О.И. , Михайлов Д.В. Роль возрастного андрогенодефицита в патогенезе аденомы предстательной железы // Тихоокеанский медицинский журнал. 2016. №1.С.14-18.
20. Шиков С.М. Медико-социальная характеристика больных доброкачественной гиперплазией предстательной железы и организация специализированной медицинской помощи в современных условиях. Дисс… канд. мед.наук. 2005г. 192с.
21. Albisini Simone, Fouad Aoun, Thierry Roumeguere, Francesco Porpiglia, Andrea Tubaro. New treatment strategies for benign prostatic hyperplasia in the frail elderly population: a systematic review // Minerva Urologica e Nefrologica. 2017. April. 69(2). pp.19-32. https://www.ncbi.nlm.nih.gov/pubmed/27681493 (Дата обращения: 2.01.19).
22. Alcaraz A.., Carballido-Rodrigues J. Quality of Life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment- the Qualiprost study // Int Urol Nephrol. 2016. May. 48(5). Pp.645-56. https://www.ncbi.nlm.nih.gov/pubmed/26810324 (Дата обращения: 5.01.19).
23. Almasri A.M., Ratz P.H., Bhatia H. et al. Rhythmic contraction generates adjustable passive stiffness in rabbit detrusor // J. Appl. Physiol. 2010. Vol. 108. P. 544–553. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774559/ (Дата обращения: 28.01.19).
24. Ansari M.A., Begum D., Islam F. Serum sex steroids, gonadotro‑ phins and sex hormonebinding globulin in prostatic hyperplasia // Ann. Saudi. Med. 2008. Vol. 28. P. 174–178. (Дата обращения: 28.01.19).
25. Bouza C., Lo ´pez T., Magro A., Navalpotro L., Amate J.M. Systematic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia // BMC Urol. 2006.6:14. https://www.ncbi.nlm.nih.gov/pubmed/16790044 (Дата обращения: 3.01.19).
26. Boyle P., Robertson C., Mazzetta C. et al. The association between lower urinary tract symptoms and erectile dysfunction in four centres // the Ur Epik study. BJU Int 2003. 92.pp. 719–25. https://www.ncbi.nlm.nih.gov/pubmed/14616454 (Дата обращения: 2.01.19).
27. Braun M., Wassmer G., Klotz T. et al. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’ // Int J Impot Res. 2000. 12.pp.305–11.
28. Brookes S.T., Link C.L., Donovan JL,McKinlay J.B. Relationship between lower urinary tract symptoms and erectile dysfuntion: results from the Boston Area Community Health Survey // J.Urol. 2008. 179. pp.250-255. https://www.ncbi.nlm.nih.gov/pubmed/18001787 (Дата обращения: 9.02.19).
29. Chitale S., Collins R., Hull S., Smith E., Irving S. Is the current practice providing an integrated approach to the management of LUTS and ED in primary care // An audit and literature review. J Sex Med. 2007. 4.pp. 1713–25. https://www.ncbi.nlm.nih.gov/pubmed/17908234 (Дата обращения: 30.01.19).
30. Cosimo De Nunzio, Claus G. RoehrBorn, Karl-Erik Andersson. Erectile dysfunction and urinary tract symptoms// EurUrol Focus.412. 2017. P. 352-363. https://www.eu-focus.europeanurology.com/article/S2405-4569(17)30260-2/pdf (Дата обращения: 06.01.19).
31. Espinosa G., Esposito R., Kazzazi A., Djavan B. Vitamin D and benign prostatic hyperplasia – a review // Can. J. Urol. 2013. Vol. 20. No. 4. P. 6820–6825. https://www.ncbi.nlm.nih.gov/pubmed/23930605 (Дата обращения: 17.01.19).
32. Fok George., Phillips C., Koyama T., Byerly, S., Concepcion, R., motley, S. S. Тhe Relationship between physical activity, lower urinary tract symptoms (LUTS) and prostate volume» // BJU Int. 2013. 111. pp.122–128.
33. Gaccia M., Corona G., Vignozzi L., Salvi M. [et al.]. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta‑analysis // BJU Int. 2015. Vol. 115. No. 1. P. 24–31. https://www.ncbi.nlm.nih.gov/pubmed/24602293 (Дата обращения: 23.01.19).
34. Gaccia M., Ian Eardleyb, Francois Giulianoc. Critical Analysis of the Relationship Between Sexual Dysfunctions and Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia // 2011 European Association of Urology. 2011. 60(4). Pp. 809-25. doi: 10.1016 / j.eururo.2011.06.037. https://www.ncbi.nlm.nih.gov/pubmed/21726934 (Дата обращения: 30.01.19).
35. Golden S.H., Robinson K.A., Saldanha I.et al. Prevalence and incidence endocrine and metabolic disorders in the United States: a comprehensive review // J Clin Endocrinol Metab. 2009. 94(6). pp.1853–78. DOI: 10.1210/jc.2008-2291. https://www.ncbi.nlm.nih.gov/pubmed/19494161 (Дата обращения: 23.01.19).
36. Gravas S., Cornu J.N., Drake M.J. et al. Treatment of Non-neurogenic Male LUTS// EAU guidelines. Ed by EAU. 2017. Pp. 1-72. http://uromed.org/guideline/treatment-of-non-neurogenic-male-luts https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/ (Дата обращения: 17.01.19).
37. Gorbachinsky I., Akpinar H., Assimos D.G. Metabolic syndrome and urological diseases // Rev. Urol. 2010. Vol. 12. No. 4. P. 157–180. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020279/ (Дата обращения: 23.02.19).
38. Gregoire Robert, Aurelien Descazeaud, Rahmene Azzouzi. Impact of Lower Urinary tract Symptoms on Discomfort in Men Aged between 50 and 80 years» // Urolint. 2010.84.Pp.424-429
39. Hoffman R.M., Monga M., Elliot S.P., Macdonald R., Wilt T.J. Microwave thermotherapy for benign prostatic hyperplasia // Cochrane Database Syst Rev. 2012. CD004135 https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004135.pub3/full. (Дата обращения: 9.01.19).
40. Holtgrewe H.L., Mebust W.K., Dowd J.B. et al. Transurethral prostatectomies: practical aspects of the dominant operation in American urology // J Urol. 2000.141: р.248. https://www.ncbi.nlm.nih.gov/pubmed/1279218 (Дата обращения: 30.12.18).
41. Hatzimouratidis K., Amar E., Eardley I. et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation // EurUrol .2010. 57: pp.804–14. https://www.ncbi.nlm.nih.gov/pubmed/20189712 (Дата обращения: 2.01.19).
42. Inman B.A., St Sauver J.L., Jacobson D.J .et al. A population-based, longitudinal study of erectile dysfunction and future coronary artery diseass // MayoClinProc.2009. 84. pp.108–13. https://www.ncbi.nlm.nih.gov/pubmed/19181643 (Дата обращения: 30.01.19).
43. Jackson G., Boon N., Eardley I. et al. Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus // Int J ClinPract. 2010. 64. pp. 848–57. https://www.ncbi.nlm.nih.gov/pubmed/20584218 (Дата обращения: 23.02.19).
44. Jacobsen S.J., Guess H.A., Panser L.et al. A population-based study of healthcare-seeking behaior for treatment of urinary symptoms. The Olmsted Country Study of Urinary Symptoms and Health Status Amond Men // Arch Fan Med. 2003. 2.pp.729-35. https://jhu.pure.elsevier.com/en/publications/a-population-based-study-of-health-careseeking-behavior-for-treat-4 (Дата обращения: 8.02.19).
45. Juhyun Park, Yang Joo Lee, Jeong-Woo Lee. Comparative analysis of the treatment of bening prostatic hyperplasia in urologists and neurologists: a study of the health insurance database throughout Korea//Seul.Borame Medical Center of Seol national University.2015. pp.233-239. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4355435/(Дата обращения: 30.01.19).
46. Kalinkova M., Orlikova M. Quality of life of eldery people//Sociological and Humanities Sciences // Slovakia. Historical and Social-Eduicational Idea. 2017.Volume 9.3/2.
47. Kirby M., Chaple C., Jackson G. et al. Erectile dysfunction and Lower Urinary tract symptoms:a consensus on the importance of co-diagnosis // int J ClinPract. July 2013. 67.7. pp.606-618. doi:10.1111/ijcp.12176. https://www.ncbi.nlm.nih.gov/pubmed/23617950 (Дата обращения: 12.01.19).
48. Kok E.T., Schouten B.W., Bohnen A.M., Groeneveld F.P., Thomas S., Bosch J.L. Risk Factors for the development of lower urinary tract symptoms indicative of benign prostatic hyperplasia in a community of healthy aging men // the Krimpen study. J. Urol. 2009. 181.pp. 710-716. https://www.ncbi.nlm.nih.gov/pubmed/19091352(Дата обращения: 22.02.19).
49. Kristal A. R., Arnold K. B., Schenk J.M., Neuhauser M. L., Goodman P., Penson D. F. Features of nutrition, the use of additives and the risk of symptomatic benign prostatic hyperplasia: the results of a study on the prevention of prostate cancer // Am J Epidemiol. 2008. 167. pp. 925–934. https://www.ncbi.nlm.nih.gov/pubmed/18263602 (Дата обращения: 7.02.19).
50. Lightner D.J., Krambeck A.E., Jacobson D.J. et al. Nocturia is associated with an increased risk of coronary heart disease and death // BJU Int .2012. 110. Pp. 848–53. https://www.ncbi.nlm.nih.gov/pubmed/22233166 (Дата обращения: 23.02.19).
51. Lim K.B. Epidemiology of clinical benign prostatic hyperplasia // Asian J Urol .2017. Jul.4(3). pp.148-151. https://www.ncbi.nlm.nih.gov/pubmed/29264223
52. Loeb S., Kettermann A., Carter H.B., et al. Prostate volume changes over time: results from the Baltimore Longitudinal Study of Aging // J Urol. 2009.182(4):Pp.1458–62. https://www.ncbi.nlm.nih.gov/pubmed/19683305 (Дата обращения: 8.02.19).
53. Magistro G., Christian G., Atief S., Christian Gratzke. Prostatic Uretral Lift Versus Trasurethral Resection of Prostate // Curr Urol Rep. 2017. 18. pp.82. https://www.ncbi.nlm.nih.gov/pubmed/28852996 (Дата обращения: 19.02.19).
54. Map of Medicine 2012. http://www.mapofmedicine.com.(accessed 20 April 2012). (Дата обращения: 30.02.19).
55. McConnel J.D., Roehrborn C.G., Bautista O.M. Medical Therapy of Prostatic Symptoms (MTOPS) Montorsi F, Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia // N Engl J Med. 2003. 349. Pp.2387–2398. https://www.ncbi.nlm.nih.gov/pubmed/14681504 Дата обращения: 27.01.19).
56. Merrill J.M., Laux L.F., Thornby J.I. Why doctors have difficulty with sex histories // South Med J .1990. 83pp. 613–7. https://www.ncbi.nlm.nih.gov/pubmed/2356491 (Дата обращения: 3.05.19).
57. Montorsi F., Henkel T., Geboers A. et al. Tffect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderateto-severe bening prostatic hyperplasia:4-year data from the CombAT study // 2010.Int J Clin Pract. 64. Pp.1042-1051. https://www.ncbi.nlm.nih.gov/pubmed/20487046 Дата обращения: 2.01.19).
58. NICE clinical guideline 97. «Lower urinary tract simptoms.Themanagment of lower urinary tract symptoms in men» // http://www.nice.org.uk/guidance/CG97/FullGuidance;. (Дата обращения: 30.01.19).
59. Pietzyk B., Olszanecka-Glinianowicz M., Owczarek A. Depressive symptoms in patients diagnosed with benign prostatic hyperplasia // Int Urol Nephrol .2015. 47:pp.431-440. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341023/ Дата обращения: 12.01.19).
60. Pao-Hwa Lina and Stephen J. Freedlandb. Lifestyle and lower urinary tract symptoms // Curr Opin Urol .2015. 25.pp.1–5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380880/ Дата обращения: 3.01.19).
61. Parsons J.K., Sarma A.V., Makvari K., Wei J.T. Obesity and benign prostatic hyperplasia: clinical connections, emergingetio logical paradigms and future directions // JUrol. 2009. 182 (Supplement 6).Pp. S27 - S31. https://www.ncbi.nlm.nih.gov/pubmed/19846130(Дата обращения: 30.01.19).
62. Parsons J.K., Im R. Alcohol use is associated with a reduced risk of benign prostatic hyperplasia // J Urol. 2009. 182. pp. 1463–1468. https://www.ncbi.nlm.nih.gov/pubmed/19683313 (Дата обращения: 8.03.19).
63. Parsons J.K.,Wilt T.J., Wang P.Y., Barrett-Connor E., Bauer D.C., Marshall L.M., et al. Progression of lower urinary tract symptoms in older men: acommunity based study // JUrol. 2010.183(5). Pp.1915-20. (Дата обращения: 25.01.19).
64. Placets E.A., Kavachi I., Rimm E.B., Willett V.K., Giovannucci E. Race. Еthnicity and benign prostatic hyperplasia in a subsequent study of health workers // J Urol .2000. 163. Pp. 490–495. https://www.ncbi.nlm.nih.gov/pubmed/10647663
65. Schenk J.M., Kristal A.R., Neuhouser M.L., Tangen C.M., White E., Lin D.W. Biomarkers of systemic inflammation and risk, symptomatic benign prostatic hyperplasia: results of a study on the prevention of prostate cancer // Am J Epidemiol. 2010. 171. Pp: 571–582. https://www.ncbi.nlm.nih.gov/pubmed/20142396 Дата обращения: 11.11.18).
66. Sells H., Donovan J., Ewings P., MacDonagh R.P. The development and validation of a quality-of-life measure to assess partner morbidity in benign prostatic hyperplasia // BJU Int. 2000. 85. Pp: 440–5. https://www.ncbi.nlm.nih.gov/pubmed/10691823 Дата обращения: 07.12.18).
67. Sexton C.C., Coyne K.S., Kopp Z.S. et al. The overlap of storage, voiding and postmicturition symptoms and implicatijns for treatment seeking in the USA, UK and Sweden // EpiLUTS BJU Int .2009.103(Supl.3). Pp:12-23. https://www.ncbi.nlm.nih.gov/pubmed/19302498 (Дата обращения: 16.12.18).
68. Vuichoud C., Loughlin K.R. Benign Prostatic Hyperplasia: epidemiology, economics and evaluation // Can J Urol. 2015. 22 (Suppl 1). Pp:1-6. https://www.ncbi.nlm.nih.gov/pubmed/26497338 Дата обращения: 30.12.18).
69. Xinyu Zhang, Bin Yang, Ni Li, and Hongjun Li. Prevalence and Risk Factors for Erectile Dysfunction in Chinese Adult Males // The Journal of Sexual Medicine. Pp:1-8. https://www.ncbi.nlm.nih.gov/pubmed/28874333 (Дата обращения: 18.01.19).
70. Yalçınkaya S., Eren E., Eroglu M. [et al.]. Deficiency of vitamin D and elevated aldosterone in prostate hyperplasia // Adv. Clin. Exp. Med. 2014. Vol. 23. No. 3. P. 441–446. https://www.ncbi.nlm.nih.gov/pubmed/24979517 (Дата обращения: 12.01.19).
Referensec:
1. Abdurahmanov A.K. Mediko-social'nye faktory i pervichnaja profilaktika dobrokachestvennoj giperplazii predstatel'noj zhelezy. (Diss…kand.med.nauk.). [Medical and social factors and primary prevention of benign prostatic hyperplasia]. 2009. 260p.
2. Aljaeva Ju.G. Bolezni predstatel'noi zhelezy. [Prostate diseases]. GJeOTAR‑Media.2009. 240 p.
3. Gigiadze O.V. Reabilitatsiya bol'nykh dobrokachestvennoi giperplaziei posle khirurgicheskogo lecheniya (dokt. diss.). [Rehabilitation of patients with benign hyperplasia after surgical treatment. Doct. Diss.]. Moskva. 2006. 255p.
4. Doshozhaev B.K. Epidemiologija dobrokachestvennoj giperplazii predstatel'noj zhelezy v populjacii muzhchin starshe 40 let v Respublike Kazahstan.[Epidemiology of benign prostatic hyperplasia in a population of men older than 40 years in the Republic of Kazakhstan]. Vestnik AGIUV. [Bulletin of the Almaty State Institute of the improvement of doctors.]. 2012. №2. Pp. 676-70.
5. Elina Ju.A. Mediko-social'naja harakteristika bol'nyh s zabolevanijami predstatel'noj zhelezy i organizacionnye osnovy profilaktiki. (diss… kand.med.nauk.). [Medico-social characteristics of patients with prostate diseases and the organizational basis for prevention]. 2012. 152p.
6. Izmajlov, R.I. Optimizacija lechenija bol'nyh dobrokachestvennoj giperplaziej predstatel'noj zhelezy bol'shih razmerov. (diss… kand.med. nauk). [Optimization of treatment of patients with benign prostatic hyperplasia of a large size]. 2010. 139 p.
7. Kalinina S.N., Burlaka O.O., Aleksandrov M.S. Diagnostika i lechenie simptomov nizhnih mochevyh putej i erektil'noi disfunktsii u bol'nykh dobrokachestvennoi giperplaziei predstatel'noi zhelezy. [Diagnosis and treatment of lower urinary tract symptoms and erectile dysfunction in patients with benign prostatic hyperplasia]. Urologicheskie vedomosti. [Urological Reports].2018.V 8.№1.Pp.26-33.
8. Kalinchenko S.Ju., Tjuzikov I.A. Zabolevaniya predstatel' noi zhelezy i metabolicheskii sindrom: novaya patogeneticheskaya kontsepciya (literaturnyi obzor). [Prostate diseases and metabolic syndrome: a new pathogenetic concept (literature review)]. Meditsinskii alfavit. Bol'nica. [Medical alphabet. Hospital]. 2011. № 4. Pp. 38–43.
9. Kamaev I.A. Aktual'nye problemy mediko-social'noj pomoshhi naseleniju starshih vozrastnyh grupp. [Actual problems of medical and social assistance to the population of older age groups]. Obshhestvennoe zdorov'e i zdravookhranenie. Izbrannye lektsii. [Public Health and Health Care. Selected lectures]. 2010.
10. Kirpatovskii V.I., Frolova E.V., Nadtochii O.N. at al. Androgennyidefitsitiprogressirovaniedobrokachestvennoigiperplaziipredstatel'noizhelezy u bol'nykh s metabolicheskim sindromom: net li protivorechiya? [Androgen deficiency and progression of benign prostatic hyperplasia in patients with metabolic syndrome: is there a contradiction?]. Andrologiya i genital'naya khirurgiya [Andrology& genital surgery]. 2017, 3; V.18; pp.10-18.
11. Kornev I.A. Alekseeva T.A., Al'-Shukri S.H. Simptomy nizhnikh mochevykh putei u muzhchin Severo-Zapadnogo regiona Rossiiskoi Federatsii: analiz rezul'tatov populyatsionnogo issledovavniya. [Symptoms of the lower urinary tract in men of the North-West region of the Russian Federation: analysis of the results of population studies]. Urologicheskie vedomosti. [Urolgic statements]. 2016. V.6. №1. pp.5-9.
12. Kyzlasov P.S., Martov A.G., Popov S.V. Erektil'naya disfunktsiya posle transuretral'noi khirurgii pri dobrokachestvennoi giperplazii predstatel'noi zhelezy. [Erectile dysfunction after transurethral surgery for benign prostatic hyperplasia]. Vestnik Volg GMU. [Bulletin of VolgGMU]. 2017. Issue 3 (63). Pp.10-15.
13. Latysheva V.Ja., Anichkin V.V, Karpovich E.V. Otsenka kachestva zhizni bol'nykh s dobrokachestvennoi giperplaziei predstatel'noi zhelezy. [Assessment of the quality of life of patients with benign prostatic hyperplasia]. Problemy zdorov'ya i ekologii. Belarus. [Problems of health and ecology. Belarus]. 2006. №1(7). Pp.142-148.
14. Lopatkina N.A.. Urologija. Natsional'noe rukovodstvo. [Urology. National Leadership]. GJeOTAR‑Media. [GEOTAR-Media]. 2009. 1024 p.
15. Panovich A.A. Organizacionnye aspekty vosstanovitel'nogo lecheniya muzhchin s dobrokachestvennoi giperplaziei predstatel'noi zhelezy. (diss...kand. med. nauk). [Organizational aspects of rehabilitation treatment of men with benign prostatic hyperplasia]. 2014. 152p.
16. Pushkar' D.Ju., Rasner I.P. Narushenie mocheispuskaniya i seksual'noi funktsii u bol'nykh dobrokachestvennoi giperplaziei predstatel'noi zhelezy. [Violation of urination and sexual function in patients with benign prostatic hyperplasia]. Vrach. [Doctor]. 2008. №6. Pp.34-38.
17. Sevryukov F.A. Kompleksnye mediko-sotsial'nye i kliniko-ekonomicheskie aspekty profilaktiki i lecheniya dobrokachestvennoii giperplazii predstatel'noi zhelezy: diss. (dokt. diss.). [Complex medico-social and clinical-economic aspects of the prevention and treatment of benign prostatic hyperplasia]. 2012. 352p.
18. Sevryukov F.A., Kamaev I.A., Grib M.N. Faktory riska i kachestvo zhizni bol'nykh s dobrokachestvennoi giperplaziei predstatel'noi zhelezy. [Risk factors and quality of life of patients with benign prostatic hyperplasia]. Rossiiskii mediko-biologicheskii vestnik imeni akademika I.P. Pavlova. [Russian Medical-Biological Journal named after academician I.P. Pavlova.]. 2011. №3. P. 48-51.
19. Tjuzikov I.A., Bratchikov O.I., Mihajlov D.V. Rol' vozrastnogo androgenodefitsita v patogeneze adenomy predstatel'noi zhelezy. [The role of age-related androgen deficiency in the pathogenesis of prostate adenoma]. Tikhookeanskii meditsinskii zhurnal. [Pacific Medical Journal]. 2016. №1. Pp.14-18.
20. Shikov S.M. Mediko-sotsial'naya kharakteristika bol'nykh dobrokachestvennoi giperplaziei predstatel'noi zhelezy i organizatsiya spetsializirovannoi meditsinskoi pomoshhi v sovremennykh usloviyakh. (diss… kand. Med.nauk). [Medico-social characteristics of patients with benign prostatic hyperplasia and the organization of specialized medical care in modern conditions]. 2005.192p.
Number of Views: 275
Category of articles:
Reviews
Bibliography link
Kussainov A.M., Bulegenov T.A. Medical and social aspects of benign prostatic hyperplasia. Literature review. Nauka i Zdravookhranenie [Science & Healthcare]. 2019, (Vol.21) 3, pp. 30-44.Related publications:
INTERRELATION OF INTRAABDOMINAL HYPERTENSION AND MARKERS OF GASTROINTESTINAL TRACT INJURY IN PATIENTS WITH MULTIORGAN DYSFUNCTION
DRUG-INDUCED LIVER INJURY AND GENDER DIFFERENCES
QUALITY OF LIFE IN PRIMARY BILIARY CHOLANGITIS AND ITS ASSESSMENT
DIAGNOSTIC AND THERAPEUTIC LAPAROSCOPY FOR ABDOMINAL INJURIES. REVIEW
METHODS FOR SCHOOL-AGE CHILDREN NUTRITIONAL STATUS ASSESSMENT: FOCUS ON ANTHROPOMETRIC PARAMETERS. A REVIEW.